EGFR and breast carcinoma: Poziotinib (HM781-36B) is a novel, irreversible EGFR/pan-HER and a member of the TEC family of nonreceptor/cytoplasmic TKI that is currently been evaluated for efficacy in the treatment of gastric cancer (NCT01746771), breast cancer (NCT02544997), non-small-cell lung cancer (NCT03066206, NCT03318939) and CRC (NCT04172597) [32,33,34,35].